AQST logo

Aquestive Therapeutics (AQST) Free Cash Flow

Annual FCF

-$7.38 M
+$4.97 M+40.25%

December 31, 2023

Summary

Performance

1-Year Change

+40.25%

3-Year Change

+83.96%

5-Year Change

+50.22%

15-Year Change

-296.35%

AQST Free Cash Flow Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

67.81%
AQST annual free cash flow is higher than 67.81% of companies in Healthcare sector

High & Low

All-time High

$3.76 M
AQST annual free cash flow is currently -296.35% below its historical high of $3.76 million

3-Year Low

-$33.89 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
AQST previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Mar 5, 2025
AQST next annual earnings announcement is scheduled for Mar 5, 2025

OtherAQSTcash flowmetrics:

Annual CFO

-$6.38 M
AQST annual cash flow from operations is -$6.38 million

Annual CFF

$3.97 M
AQST annual cash flow from financing activities is $3.97 million

Annual CFI

-$995.00 K
AQST annual cash flow from investing activities is -$995.00 thousand

Annual CAPEX

$995.00 K
AQST annual capital expenditures is $995.00 thousand

Quarterly FCF

-$11.96 M
-$4.92 M-69.86%

September 30, 2024

Summary

Performance

3-Month Change

-69.86%

1-Year Change

-378.78%

3-Year Change

-378.78%

5-Year Change

-378.78%

AQST Quarterly FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

29.55%
AQST quarterly free cash flow is higher than 29.55% of companies in Healthcare sector

High & Low

All-time High

$15.19 M
AQST quarterly free cash flow is currently -178.72% below its historical high of $15.19 million

3-Year Low

-$14.59 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
AQST previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 5, 2025
AQST next earnings announcement is scheduled for Mar 5, 2025

OtherAQSTcash flowmetrics:

Quarterly CFO

-$11.88 M
AQST quarterly cash flow from operations is -$11.88 million

Quarterly CFF

-$17.00 K
AQST quarterly cash flow from financing activities is -$17.00 thousand

Quarterly CFI

-$80.00 K
AQST quarterly cash flow from investing activities is -$80.00 thousand

Quarterly CAPEX

$80.00 K
AQST quarterly capital expenditures is $80.00 thousand

TTM FCF

-$34.37 M
-$9.46 M-37.98%

September 30, 2024

Summary

Performance

3-Month Change

-37.98%

1-Year Change

-675.46%

3-Year Change

-675.46%

5-Year Change

-675.46%

AQST TTM FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

37.5%
AQST TTM free cash flow is higher than 37.5% of companies in Healthcare sector

High & Low

All-time High

$11.25 M
AQST TTM free cash flow is currently -405.45% below its historical high of $11.25 million

3-Year Low

-$39.57 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
AQST previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 5, 2025
AQST next earnings announcement is scheduled for Mar 5, 2025

OtherAQSTcash flowmetrics:

TTM CFO

-$34.21 M
AQST TTM cash flow from operations is -$34.21 million

TTM CFF

$87.35 M
AQST TTM cash flow from financing activities is $87.35 million

TTM CFI

-$160.00 K
AQST TTM cash flow from investing activities is -$160.00 thousand

TTM CAPEX

$160.00 K
AQST TTM capital expenditures is $160.00 thousand

Free Cash Flow Formula

FCF = Cash From Operations − CAPEX

Annual FCF

-$7.38 M
AQST annual free cash flow is -$7.38 million

Annual CFO

-$6.38 M
AQST annual cash flow from operations is -$6.38 million

Annual CAPEX

$995.00 K
AQST annual capital expenditures is $995.00 thousand

AQST Free Cash Flow Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+40.3%-378.8%-675.5%
3 y3 years+84.0%-378.8%-675.5%
5 y5 years+50.2%-378.8%-675.5%

AQST Free Cash Flow Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+78.2%-235.7%+18.0%-410.9%+13.1%
5 y5-yearat high+87.9%-235.7%+18.0%-410.9%+43.5%
alltimeall time-296.4%+87.9%-178.7%+33.8%-405.4%+43.5%

Aquestive Therapeutics Free Cash Flow History

DateAnnualQuarterlyTTM
Sep 2024
-
-$11.96 M(+69.9%)
-$34.37 M(+38.0%)
Jun 2024
-
-$7.04 M(-32.4%)
-$24.91 M(-6.4%)
Mar 2024
-
-$10.41 M(+110.0%)
-$26.60 M(+260.7%)
Dec 2023
-$7.38 M(-40.2%)
-$4.96 M(+98.5%)
-$7.38 M(-223.5%)
Sep 2023
-
-$2.50 M(-71.4%)
$5.97 M(-37.5%)
Jun 2023
-
-$8.73 M(-199.1%)
$9.56 M(-13.5%)
Mar 2023
-
$8.81 M(+5.1%)
$11.06 M(-189.6%)
Dec 2022
-$12.34 M(-63.6%)
$8.39 M(+668.3%)
-$12.34 M(-57.9%)
Sep 2022
-
$1.09 M(-115.1%)
-$29.33 M(-25.9%)
Jun 2022
-
-$7.24 M(-50.4%)
-$39.57 M(+15.4%)
Mar 2022
-
-$14.59 M(+69.7%)
-$34.28 M(+1.1%)
Dec 2021
-$33.89 M(-26.3%)
-$8.59 M(-6.1%)
-$33.89 M(-13.2%)
Sep 2021
-
-$9.15 M(+369.1%)
-$39.05 M(+2.1%)
Jun 2021
-
-$1.95 M(-86.3%)
-$38.25 M(-17.6%)
Mar 2021
-
-$14.20 M(+3.3%)
-$46.41 M(+0.9%)
Dec 2020
-$45.98 M
-$13.75 M(+64.6%)
-$45.98 M(+7.2%)
DateAnnualQuarterlyTTM
Sep 2020
-
-$8.35 M(-17.4%)
-$42.89 M(-13.2%)
Jun 2020
-
-$10.11 M(-26.6%)
-$49.42 M(-12.7%)
Mar 2020
-
-$13.77 M(+29.1%)
-$56.59 M(-7.0%)
Dec 2019
-$60.87 M(+310.9%)
-$10.66 M(-28.4%)
-$60.87 M(+13.8%)
Sep 2019
-
-$14.88 M(-13.9%)
-$53.51 M(+5.8%)
Jun 2019
-
-$17.28 M(-4.3%)
-$50.56 M(+51.4%)
Mar 2019
-
-$18.06 M(+446.8%)
-$33.40 M(+125.4%)
Dec 2018
-$14.81 M(-494.4%)
-$3.30 M(-72.3%)
-$14.81 M(-22.1%)
Sep 2018
-
-$11.92 M(>+9900.0%)
-$19.01 M(-334.5%)
Jun 2018
-
-$116.00 K(-122.1%)
$8.11 M(+686.3%)
Mar 2018
-
$526.00 K(-107.0%)
$1.03 M(-72.6%)
Dec 2017
$3.76 M(-141.0%)
-$7.50 M(-149.3%)
$3.76 M(-66.6%)
Sep 2017
-
$15.19 M(-311.3%)
$11.25 M(-385.5%)
Jun 2017
-
-$7.19 M(-321.2%)
-$3.94 M(-221.2%)
Mar 2017
-
$3.25 M
$3.25 M
Dec 2016
-$9.15 M
-
-

FAQ

  • What is Aquestive Therapeutics annual free cash flow?
  • What is the all time high annual FCF for Aquestive Therapeutics?
  • What is Aquestive Therapeutics annual FCF year-on-year change?
  • What is Aquestive Therapeutics quarterly free cash flow?
  • What is the all time high quarterly FCF for Aquestive Therapeutics?
  • What is Aquestive Therapeutics quarterly FCF year-on-year change?
  • What is Aquestive Therapeutics TTM free cash flow?
  • What is the all time high TTM FCF for Aquestive Therapeutics?
  • What is Aquestive Therapeutics TTM FCF year-on-year change?

What is Aquestive Therapeutics annual free cash flow?

The current annual FCF of AQST is -$7.38 M

What is the all time high annual FCF for Aquestive Therapeutics?

Aquestive Therapeutics all-time high annual free cash flow is $3.76 M

What is Aquestive Therapeutics annual FCF year-on-year change?

Over the past year, AQST annual free cash flow has changed by +$4.97 M (+40.25%)

What is Aquestive Therapeutics quarterly free cash flow?

The current quarterly FCF of AQST is -$11.96 M

What is the all time high quarterly FCF for Aquestive Therapeutics?

Aquestive Therapeutics all-time high quarterly free cash flow is $15.19 M

What is Aquestive Therapeutics quarterly FCF year-on-year change?

Over the past year, AQST quarterly free cash flow has changed by -$9.46 M (-378.78%)

What is Aquestive Therapeutics TTM free cash flow?

The current TTM FCF of AQST is -$34.37 M

What is the all time high TTM FCF for Aquestive Therapeutics?

Aquestive Therapeutics all-time high TTM free cash flow is $11.25 M

What is Aquestive Therapeutics TTM FCF year-on-year change?

Over the past year, AQST TTM free cash flow has changed by -$40.34 M (-675.46%)